Opus Genetics, Inc.
IRD
$4.90
-$0.29-5.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.15% | 74.60% | -6.25% | -28.19% | -42.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.15% | 74.60% | -6.25% | -28.19% | -42.30% |
| Cost of Revenue | 14.54% | 15.52% | 64.61% | 78.43% | 51.98% |
| Gross Profit | -4.41% | 16.85% | -738.32% | -841.24% | -1,242.75% |
| SG&A Expenses | 20.99% | 72.49% | 67.58% | 39.14% | 52.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.15% | 36.86% | 65.87% | 60.34% | 52.19% |
| Operating Income | -13.28% | -26.13% | -144.53% | -198.97% | -222.58% |
| Income Before Tax | 13.80% | -150.80% | -313.50% | -419.27% | -476.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.80% | -150.82% | -313.15% | -418.72% | -476.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.80% | -150.82% | -313.15% | -418.72% | -476.13% |
| EBIT | -13.28% | -26.13% | -144.53% | -198.97% | -222.58% |
| EBITDA | -13.15% | -26.02% | -144.44% | -198.98% | -222.70% |
| EPS Basic | 60.16% | -62.23% | -234.28% | -317.85% | -340.15% |
| Normalized Basic EPS | 27.14% | 22.61% | -63.63% | -124.33% | -141.61% |
| EPS Diluted | 60.16% | -62.23% | -228.62% | -309.84% | -331.48% |
| Normalized Diluted EPS | 27.14% | 22.61% | -60.30% | -119.16% | -135.88% |
| Average Basic Shares Outstanding | 132.55% | 99.28% | 62.22% | 29.25% | 23.76% |
| Average Diluted Shares Outstanding | 132.55% | 99.28% | 60.60% | 27.88% | 22.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |